Results 101 to 110 of about 2,108 (191)

Inflammation and Occlusive Retinal Vasculitis Post Faricimab

JAMA Ophthalmology
ImportanceRandomized clinical trials have shown the safety and efficacy of faricimab as a novel vascular endothelial growth factor and angiopoietin-2 inhibitor in the treatment of neovascular age-related macular degeneration (nAMD) and macular edema of various etiologies.
Bruening, Will, Kim, Sean, Yeh, Steven, Rishi, Pukhraj, Conrady, Christopher D.   +4 more
openaire   +2 more sources

Intravitreal faricimab for treatment naïve patients with neovascular age-related macular degeneration: a real-world prospective study

International Journal of Retina and Vitreous
Background Intravitreal faricimab, a bispecific antibody targeting both angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A), was recently introduced for the treatment of neovascular age-related macular degeneration (nAMD), diabetic ...
Gabriela Grimaldi, Giuseppe Cancian, Arianna Paris, Michele Clerici, Giulio Volpe, Moreno Menghini   +5 more
doaj   +1 more source

Advancements in the Treatment of Diabetic Macular Edema: Current Strategies and Future Directions [PDF]

This narrative review examines current and emerging treatment strategies for diabetic macular edema (DME), a complication of diabetic retinopathy characterised by fluid accumulation in the macula, which can lead to vision impairment. The incidence of DME
Bachurska, Dominika, Czach, Magdalena, Czach, Zuzanna, Kopacz, Wojciech, Kruczyk, Barbara, Mazurek, Wojciech, Mazurek, Łukasz, Olędzka, Joanna, Piętak, Mateusz, Rękas, Barbara, Stradczuk , Monika   +10 more
core   +1 more source

Efficacy and safety of intravitreal faricimab for neovascular age-related macular degeneration: a systematic review and meta-analysis

Scientific Reports
We conducted a systematic review and meta-analysis to evaluate the visual, anatomical, and safety outcomes of the intravitreal faricimab, a novel vascular endothelial growth factor (VEGF)/angiopoietin-2 (Ang-2) bispecific agent, in neovascular age ...
Wei-Ting Yen, Chen-Shu Wu, Chang-Hao Yang, Yi-Hao Chen, Cho-Hao Lee, Cherng-Ru Hsu   +5 more
doaj   +1 more source

One-Year Outcomes of Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Ophthalmology and Therapy
Introduction This study evaluates the efficacy and safety of faricimab in a real-world cohort of treatment-naïve patients with neovascular age-related macular degeneration (nAMD).
Anne Tillmann, Richard Stillenmunkes, Justus G. Garweg, Jennifer Cattaneo, Nicolò Bartolomeo, Gabriela Grimaldi, Tahm Spitznagel, Eva C. De Oliveira Figueiredo, Aude Ambresin, Moreno Menghini, Gábor M. Somfai, Sandrine Zweifel, Jacqueline Fröhlich, Dmitri Artemiev, Andreas Ebneter, Katja Hatz, Andreas Weinberger, Isabel B. Pfister, Christin Schild, Chiara Eandi, Marion R. Munk, Swiss Retina Research Network   +21 more
doaj   +1 more source

The Impact of Disease Activity Criteria on Extending Injection Intervals in Real-World Patients with Neovascular Age-Related Macular Degeneration. [PDF]

INTRODUCTION: In clinical practice, intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection intervals for patients with neovascular age-related macular degeneration (nAMD) are based on disease activity, with active or recurrent disease

core   +1 more source

Faricimab: expanding horizon beyond VEGF [PDF]

Eye, 2019
Sharma A., Kumar N., Kuppermann B. D., Bandello F., Loewenstein A.   +4 more
openaire   +4 more sources

Morphologic Changes of Macular Choroidal Neovascularization on OCT Angiography Following Faricimab Therapy in Patients With AMD. [PDF]

J Vitreoretin Dis
Loya A, Chen V, Siddiqui T, Rao P, Chang EY.   +4 more
europepmc   +1 more source

Real-World Outcomes of Switching to Faricimab in Treatment-Experienced and Resistant Neovascular Age-Related Macular Degeneration: A Single-Centre Retrospective Study. [PDF]

Clin Ophthalmol
Stewart C, Bhangu JS, Swarnkar PK, Rifat M, Khalid S, Al-Janabi A, Awad MH, Williams GS.   +7 more
europepmc   +1 more source

Short-term real-world outcomes of switching to faricimab in anti-VEGF-refractory retinal vein occlusion: a prospective study. [PDF]

BMC Ophthalmol
Kilani A, Assaf A, Vogt D, Vounotrypidis E, Parlak M, Jochem C, Wolf A.   +6 more
europepmc   +1 more source